Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years (vol 25, pg 1197, 2010)

被引：1
|
作者：
Kim, Young-Jae [1 ]
Kim, Kyung-Tai [1 ]
Kim, Jae-Hoon [2 ]
Cha, Soon-Do [3 ]
Kim, Jae Weon [4 ]
Bae, Duk-Soo [5 ]
Nam, Joo-Hyun [6 ]
Ahn, Woong-Shick [7 ]
Choi, Ho-Sun [8 ]
Ng, Timothy [9 ]
Bi, Dan [9 ]
Ok, Jin-Ju [9 ]
Descamps, Dominique [9 ]
Bock, Hans L. [9 ]
机构：
[1] Hanyang Univ Hosp, Dept Obstet & Gynecol, Seoul, South Korea
[2] Yonsei Univ, Dept Obstet & Gynecol, Gangnam Severance Hosp, Seoul 120749, South Korea
[3] Keimyung Univ, Dept Obstet & Gynecol, Dongsan Med Ctr, Taegu, South Korea
[4] Seoul Natl Univ Hosp, Dept Obstet & Gynecol, Seoul 110744, South Korea
[5] Sungkyunkwan Univ, Dept Obstet & Gynecol, Samsung Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Dept Obstet & Gynecol, Asan Med Ctr, Seoul, South Korea
[7] Catholic Univ Korea, Dept Obstet & Gynecol, Seoul St Marys Hosp, Seoul, South Korea
[8] Chonnam Natl Univ Hosp, Dept Obstet & Gynecol, Kwangju, South Korea
[9] GlaxoSmithKline Biol, Wavre, Belgium
来源：
JOURNAL OF KOREAN MEDICAL SCIENCE | 2010年 / 25卷 / 12期
关键词：
D O I：
10.3346/jkms.2010.25.12.1831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1831 / 1831
页数：1
相关论文
共 50 条
  • [21] Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04 Adjuvanted Vaccine in Healthy Males Aged 10-18 Years
    Lehtinen, M.
    Petaja, T.
    Keranen, H.
    Karppa, T.
    Kawa, A.
    Lantela, S.
    Levanen, H.
    Tocklin, T.
    Godeaux, O.
    Dubin, G.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E174 - E174
  • [22] Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix®): A Guide to Its Two-Dose Schedule in Girls Aged 9-14 Years in the EU
    Lyseng-Williamson, Katherine A.
    PEDIATRIC DRUGS, 2014, 16 (03) : 247 - 253
  • [23] Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature
    Schwarz, Tino F.
    Leo, Oberdan
    GYNECOLOGIC ONCOLOGY, 2008, 110 (03) : S1 - S10
  • [24] A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
    Schwarz, Tino F.
    Huang, Li-Min
    Valencia, Alejandra
    Panzer, Falko
    Chiu, Cheng-Hsun
    Decreux, Annabelle
    Poncelet, Sylviane
    Karkada, Naveen
    Folschweiller, Nicolas
    Lin, Lan
    Dubin, Gary
    Struyf, Frank
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (7-8) : 1970 - 1979
  • [25] Correlation between levels of human papillomavirus (HPV)-16 and-18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
    Schwarz, Tino F.
    Kocken, Marielle
    Petaja, Tiina
    Einstein, Mark H.
    Spaczynski, Marek
    Louwers, Jacqueline A.
    Pedersen, Court
    Levin, Myron
    Zahaf, Toufik
    Poncelet, Sylviane
    Hardt, Karin
    Descamps, Dominique
    Dubin, Gary
    HUMAN VACCINES, 2010, 6 (12): : 1054 - 1061
  • [26] Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
    Bonanni, Paolo
    Gabutti, Giovanni
    Demarteau, Nadia
    Boccalini, Sara
    La Torre, Giuseppe
    BMC INFECTIOUS DISEASES, 2015, 15
  • [27] Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
    Paolo Bonanni
    Giovanni Gabutti
    Nadia Demarteau
    Sara Boccalini
    Giuseppe La Torre
    BMC Infectious Diseases, 15
  • [28] Risk of Autoimmune Diseases (AD) After Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine Immunization in Women Aged 9 to 25 Years in the United Kingdom: An Observational Cohort Study
    Willame, Corinne
    Rosillon, Dominique
    Zima, Julia
    Angelo, Maria-Genalin
    Stuurman, Anke
    Vroling, Hilde
    van Staa, Tjeerd
    Boggon, Rachael
    Bunge, Eveline
    Pladevall-Vila, Manel
    Baril, Laurence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 409 - 409
  • [29] Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Michele Kohli
    Donna Lawrence
    Jennifer Haig
    Andrea Anonychuk
    Nadia Demarteau
    BMC Public Health, 12
  • [30] Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Kohli, Michele
    Lawrence, Donna
    Haig, Jennifer
    Anonychuk, Andrea
    Demarteau, Nadia
    BMC PUBLIC HEALTH, 2012, 12
12345